Choueiri, T., Powles, T., Burotto, M., Bourlon, M., Zurawski, B., Oyervides Juárez, V. M., . . . Motzer, R. (2020). 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. Kluwer university press.
Cita Chicago Style (17a ed.)Choueiri, T.K, et al. 696O_PR Nivolumab + Cabozantinib Vs Sunitinib in First-line Treatment for Advanced Renal Cell Carcinoma: First Results from the Randomized Phase III CheckMate 9ER Trial. Kluwer university press, 2020.
Cita MLA (9a ed.)Choueiri, T.K, et al. 696O_PR Nivolumab + Cabozantinib Vs Sunitinib in First-line Treatment for Advanced Renal Cell Carcinoma: First Results from the Randomized Phase III CheckMate 9ER Trial. Kluwer university press, 2020.